Monument Therapeutics

Pharmaceuticals
Early Growth
2021

Monument Therapeutics is a stratified medicine company, that has developed novel digital biomarkers to improve neuroscience drug development. The company is initially focused on two indications for which there are no approved treatments: cognitive impairment in schizophrenia and post-operative cognitive dysfunction (“POCD”). The opportunity is therefore to follow therapeutics through from R&D to the market, where the biomarkers would serve as companion diagnostics.

Monument Therapeutics is repurposing drugs in combination with proprietary cognitive stratification tools to identify the patient sub-groups that are most likely to benefit. This contrasts the years of neuroscience drug development that have been plagued by subjective diagnoses and clinical endpoints.

Our Approach

What do we look for?

Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.

We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors.

learn more

Our Team

Corinne Lawrence

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
Enderby
Leicester
LE19 4XT

Tel: 0116 238 8200

email